I am a physician-scientist with expertise in hematology and oncology, I have more than ten years of experience as a hematologist. I had excellent postdoctoral training and gained extensive experience and knowledge of cutting-edge translational research about epigenetic regulation in blood cancers. My research interests cover epigenetics, multiple-genomics, blood cancer biology, hematopoietic stem cells/cancer stem cells, T-cell immunity, and translational target therapeutics. I have studied how mutations of chromatin regulators impact hematopoiesis, leukemia relapse, and therapy resistance using conditional mouse models, patient-derived xenograft (PDX), and multi-omics technologies. Findings from my work include 1) demonstration of the critical role of ASXL2 in myeloid malignancies; 2) elucidation of the aberrant epigenetic landscape underlying the mechanism of relapse of acute lymphoblastic leukemia and mantle cell lymphoma driven by NSD2 mutation; and 3) utilizing the insight of epigenetic mechanisms and developing novel targeting therapies to overcome glucocorticoid resistance driven by NSD2 mutation. My long-term research goal is to understand the role of chromatin regulators in normal and malignant hematopoiesis, demonstrate the molecular mechanisms underlying the initiation and relapse of blood cancers, and ultimately develop novel and effective therapies to help patients suffering from blood cancers.